Pyxis Oncology, Inc. (PYXS) stock
PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.17 (-10.76%)
Close on Nov 16, 2026Market cap $117.61MP/E –Yield –
Pyxis Oncology r&d expenses
Research and development expenses are spending on new products and technology.
Pyxis Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $75.56M, up 14.6% year over year. For fiscal 2025 it was $73.70M, up 25.4% from the year before. The highest annual figure on record is $86.13M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.70M | +25.4% |
| FY2024 | Dec 31, 2024 | $58.75M | +18.5% |
| FY2023 | Dec 31, 2023 | $49.59M | -42.4% |
| FY2022 | Dec 31, 2022 | $86.13M | +68.7% |
| FY2021 | Dec 31, 2021 | $51.05M | +464.3% |
| FY2020 | Dec 31, 2020 | $9.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.06M | -6.3% |
| Q1 FY2026 | Mar 31, 2026 | $19.98M | +17.2% |
| Q4 FY2025 | Dec 31, 2025 | $21.71M | +54.8% |
| Q3 FY2025 | Sep 30, 2025 | $17.81M | +0.4% |
| Q2 FY2025 | Jun 30, 2025 | $17.13M | +22.8% |
| Q1 FY2025 | Mar 31, 2025 | $17.04M | +30.8% |
| Q4 FY2024 | Dec 31, 2024 | $14.02M | +20.8% |
| Q3 FY2024 | Sep 30, 2024 | $17.74M | +20.8% |
| Q2 FY2024 | Jun 30, 2024 | $13.95M | +22.5% |
| Q1 FY2024 | Mar 31, 2024 | $13.03M | +9.5% |
| Q4 FY2023 | Dec 31, 2023 | $11.61M | -61.1% |
| Q3 FY2023 | Sep 30, 2023 | $14.69M | -22.8% |
| Q2 FY2023 | Jun 30, 2023 | $11.39M | -33.7% |
| Q1 FY2023 | Mar 31, 2023 | $11.90M | -40.7% |
| Q4 FY2022 | Dec 31, 2022 | $29.85M | +313.1% |
| Q3 FY2022 | Sep 30, 2022 | $19.03M | +142.5% |
| Q2 FY2022 | Jun 30, 2022 | $17.17M | +435.7% |
| Q1 FY2022 | Mar 31, 2022 | $20.07M | -38.8% |
| Q4 FY2021 | Dec 31, 2021 | $7.23M | +130.2% |
| Q3 FY2021 | Sep 30, 2021 | $7.85M | +223.7% |
| Q2 FY2021 | Jun 30, 2021 | $3.21M | – |
| Q1 FY2021 | Mar 31, 2021 | $32.77M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.14M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.43M | – |
See a number that looks wrong?